生长刺激表达基因2蛋白因子在新型冠状病毒肺炎患者心血管事件诊断及预后判断中的作用和应用前景

Role and application prospect of growth stimulation expressed gene 2 factor in diagnosis and prognosis of cardiovascular events in patients with coronavirus disease 2019

新型冠状病毒肺炎疫情自武汉爆发以来,已在全国范围出现流行趋势。对危重症患者临床救治过程中发现,患有心血管疾病、糖尿病等基础疾病的老年患者死亡风险更高。同时发现多数危重症患者出现心肌损伤、心功能衰竭等心血管功能受损情况,临床迫切需要能够尽早识别心肌损伤的指标和方法,这对提高新型冠状病毒肺炎危重症患者的救治成功率至关重要。生长刺激表达基因2蛋白(ST2)是一种血浆蛋白,是白介素-33的配体,作为新型心力衰竭及心肌损伤标志物,依据其独特信号传导通路和病理生理机制,有望与脑利钠肽等指标联合应用,对新型冠状病毒肺炎患者心力衰竭及心肌损伤诊疗及预后提供参考依据。

Since the outbreak of coronavirus disease 2019(COVID-19)in Wuhan,the epidemic subsequently reached other provinces in China.From the clinical treatment of critical patients,evidence shows that the elderly patients with cardiovascular diseases,diabetes and other underlying medical conditions have higher risk of death.Meanwhile,COVID-19 patients were found to be bearing myocardial damage,heart failure and other cardiovascular function impairment.It is quite urgent for us to identify the indicators and detection methods of myocardial injury as soon as possible,which is of great importance to improve the success rate of rescuing critical patients with COVID-19.Growth stimulation expressed gene 2(ST2),a plasma protein,is confirmed to act as a decoy receptor for interleukin-33.Based on its unique signal transduction pathway and pathophysiological mechanism,ST2,a novel cardiac marker for heart failure and myocardial injury,is expected to be combined with B-type natriuretic peptide(BNP)and other indicators to provide a reference of diagnosis and treatment for heart failure and myocardial damage in COVID-19 patients.